Trial Search Results

Seal, Stopping Atopic Dermatitis and Allergy Study

This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 10 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Jewish Health

Stanford Investigator(s):


  • Combination Product: Tri-lipid skin barrier cream (Epiceram)
  • Combination Product: Fluticasone propionate Cream 0.05%


Phase 1/Phase 2


Inclusion Criteria:

   1. Participants who develop early onset atopic dermatitis up to 10 weeks of age.

   2. Stated willingness to comply with all study procedures and availability for the
   duration of the study

   3. In good general health as evidenced by medical history

Exclusion Criteria:

   1. Infants that are small for gestational age

   2. Infants with a chronic disease requiring therapy (e.g. heart disease, diabetes,
   serious neurological defects),

   3. parents or guardians unwilling to sign consent.

Ages Eligible for Study

N/A - 10 Weeks

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kari Nadeau, M.D., PhD